323 related articles for article (PubMed ID: 25189721)
21. Familial essential thrombocythemia with spontaneous megakaryocyte colony formation and acquired JAK2 mutations.
Higgs JR; Sadek I; Neumann PE; Ing VW; Renault NK; Berman JN; Greer WL
Leukemia; 2008 Aug; 22(8):1551-6. PubMed ID: 18496561
[TBL] [Abstract][Full Text] [Related]
22. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias.
Kralovics R; Indrak K; Stopka T; Berman BW; Prchal JF; Prchal JT
Blood; 1997 Sep; 90(5):2057-61. PubMed ID: 9292543
[TBL] [Abstract][Full Text] [Related]
23. Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.
Nelson ND; Marcogliese A; Bergstrom K; Scheurer M; Mahoney D; Bertuch AA
Pediatr Blood Cancer; 2016 Aug; 63(8):1484-7. PubMed ID: 27100794
[TBL] [Abstract][Full Text] [Related]
24. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome.
Giona F; Teofili L; Moleti ML; Martini M; Palumbo G; Amendola A; Mazzucconi MG; Testi AM; Pignoloni P; Orlando SM; Capodimonti S; Nanni M; Leone G; Larocca LM; Foà R
Blood; 2012 Mar; 119(10):2219-27. PubMed ID: 22262773
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests.
Tefferi A; Pardanani A
Mayo Clin Proc; 2007 May; 82(5):599-604. PubMed ID: 17493421
[TBL] [Abstract][Full Text] [Related]
26. "Benign erythrocytosis" and other familial and congenital polycythemias.
Prchal JT; Sokol L
Eur J Haematol; 1996 Oct; 57(4):263-8. PubMed ID: 8982288
[TBL] [Abstract][Full Text] [Related]
27. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
28. A new point mutation in EPOR inducing a short deletion in congenital erythrocytosis.
Chauveau A; Luque Paz D; Lecucq L; Le Gac G; Le Maréchal C; Gueguen P; Berthou C; Ugo V
Br J Haematol; 2016 Feb; 172(3):475-7. PubMed ID: 26010769
[No Abstract] [Full Text] [Related]
29. Familial polycythemia due to truncations of the erythropoietin receptor.
Forget BG; Degan BA; Arcasoy MO
Trans Am Clin Climatol Assoc; 2000; 111():38-44; discussion 44-5. PubMed ID: 10881330
[TBL] [Abstract][Full Text] [Related]
30. Germline MPL mutations may be a rare cause of "triple-negative" thrombocytosis.
Borsani O; Pietra D; Casetti IC; Vanni D; Riccaboni G; Catricalà S; Grazia B; Boveri E; Arcaini L; Rumi E
Exp Hematol; 2024 Jan; 129():104127. PubMed ID: 37939832
[TBL] [Abstract][Full Text] [Related]
31. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene.
El-Harith el-HA; Roesl C; Ballmaier M; Germeshausen M; Frye-Boukhriss H; von Neuhoff N; Becker C; Nürnberg G; Nürnberg P; Ahmed MA; Hübener J; Schmidtke J; Welte K; Stuhrmann M
Br J Haematol; 2009 Jan; 144(2):185-94. PubMed ID: 19036112
[TBL] [Abstract][Full Text] [Related]
32. Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis.
Rives S; Pahl HL; Florensa L; Bellosillo B; Neusuess A; Estella J; Debatin KM; Kohne E; Schwarz K; Cario H
Haematologica; 2007 May; 92(5):674-7. PubMed ID: 17488692
[TBL] [Abstract][Full Text] [Related]
33. JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.
Gangat N; Szuber N; Pardanani A; Tefferi A
Leukemia; 2021 Aug; 35(8):2166-2181. PubMed ID: 34021251
[TBL] [Abstract][Full Text] [Related]
34. Erythrocytosis: genes and pathways involved in disease development.
Gašperšič J; Kristan A; Kunej T; Zupan IP; Debeljak N
Blood Transfus; 2021 Nov; 19(6):518-532. PubMed ID: 33370224
[TBL] [Abstract][Full Text] [Related]
35. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
36. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
37. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.
Marty C; Saint-Martin C; Pecquet C; Grosjean S; Saliba J; Mouton C; Leroy E; Harutyunyan AS; Abgrall JF; Favier R; Toussaint A; Solary E; Kralovics R; Constantinescu SN; Najman A; Vainchenker W; Plo I; Bellanné-Chantelot C
Blood; 2014 Feb; 123(9):1372-83. PubMed ID: 24398328
[TBL] [Abstract][Full Text] [Related]
38. JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.
Gangat N; Szuber N; Tefferi A
Am J Hematol; 2023 Jun; 98(6):965-981. PubMed ID: 36966432
[TBL] [Abstract][Full Text] [Related]
39. A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family.
Liu K; Kralovics R; Rudzki Z; Grabowska B; Buser AS; Olcaydu D; Gisslinger H; Tiedt R; Frank P; Okoñ K; van der Maas AP; Skoda RC
Haematologica; 2008 May; 93(5):706-14. PubMed ID: 18367486
[TBL] [Abstract][Full Text] [Related]
40. Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients.
Al-Harbi T; Al-Zahrani M; Al-Balwi M; Al-Hazmi A; Alsuhaibani A; Aljafn N; Alsumari F; Aleshaiwi L; Alsuhibani A; Alqasim O; Ahmad N
Br J Haematol; 2021 Sep; 194(5):893-898. PubMed ID: 34131895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
